Paclitaxel-carboplatin-gemcitabine (TCG) as first-line treatment of ovarian cancer: A prospective multicenter phase II study (AGO-OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) comparing TCG with standard TC

International Journal of Gynecological Cancer

Volumn 15, Issue 6 SUPPL. 3, 2005, Pages 224-225

  Du Bois, A ^a   Sehouli, J ^a   Lund, B ^b   Joly, F ^c   Huober, J ^a   Jensen, T S ^b   Levy, E ^c   Heilmann, V ^a   Boman, K ^b   Hardy Bessard, A C ^c   Burges, A ^a   Maenpaa J ^b   Pujade Lauraine, E ^c   Pfisterer, J ^a   Gropp, M ^a   Staehle, A ^a   Wimberger, P ^a   Jackisch, C ^a   Schmalfeldt, B ^a   Belau, A ^a   Loibl, S ^a   Wollschlaeger, K ^a   Canzler, U ^a   Rochon, J ^a   more..

^a AGO OVAR   (Germany)

^b NSGO Scandinavia   (Sweden)

^c GINECO   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CARBOPLATIN PLUS GEMCITABINE PLUS PACLITAXEL; CARBOPLATIN PLUS PACLITAXEL; GEMCITABINE; PACLITAXEL; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUTROPENIA; OVARY CANCER; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

EID: 30744461646     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2005.00440.x     Document Type: Article

References (0)